Literature DB >> 8611058

Six-month follow-up of naltrexone and psychotherapy for alcohol dependence.

S S O'Malley1, A J Jaffe, G Chang, S Rode, R Schottenfeld, R E Meyer, B Rounsaville.   

Abstract

BACKGROUND: The goal of this study was to examine the persistence of naltrexone's effects on drinking outcomes among alcoholics following discontinuation of treatment and to determine whether coping skills therapy improves long-term outcomes compared with supportive therapy.
METHODS: Eighty of 97 alcohol-dependent subjects randomized to receive naltrexone or placebo and either coping skills therapy or supportive therapy for 12 weeks were assessed at a 6-month off-treatment follow-up.
RESULTS: Subjects who received naltrexone were less likely to drink heavily or to meet criteria for alcohol abuse or dependence than subjects who received placebo. The effect of naltrexone therapy on abstinence rates persisted only through the first month of follow-up. Coping skills therapy was associated with decreased levels of drinking among subjects who received placebo. Psychotherapy condition, however, did not predict alcohol diagnosis at follow-up.
CONCLUSIONS: Some but not all of the benefits resulting from short-term naltrexone treatment persist after discontinuation of treatment. The findings suggest that continued treatment with naltrexone may be beneficial for some patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611058     DOI: 10.1001/archpsyc.1996.01830030039007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  46 in total

1.  Cognitive-behavioral therapy plus contingency management for cocaine use: findings during treatment and across 12-month follow-up.

Authors:  David H Epstein; Wesley E Hawkins; Lino Covi; Annie Umbricht; Kenzie L Preston
Journal:  Psychol Addict Behav       Date:  2003-03

2.  Rationale for Using Exercise in the Treatment of Stimulant Use Disorders.

Authors:  Tracy L Greer; Kolette M Ring; Diane Warden; Bruce D Grannemann; Timothy S Church; Eugene Somoza; Steven N Blair; Jose Szapocznik; Mark Stoutenberg; Chad Rethorst; Robrina Walker; David W Morris; Andrzej S Kosinski; Tiffany Kyle; Bess Marcus; Becca Crowell; Neal Oden; Edward Nunes; Madhukar H Trivedi
Journal:  J Glob Drug Policy Pract       Date:  2012

3.  Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less.

Authors:  Kathleen M Carroll; Charla Nich; Donna M Lapaglia; Erica N Peters; Caroline J Easton; Nancy M Petry
Journal:  Addiction       Date:  2012-05-08       Impact factor: 6.526

Review 4.  Evidence-based practices for substance use disorders.

Authors:  Mark P McGovern; Kathleen M Carroll
Journal:  Psychiatr Clin North Am       Date:  2003-12

Review 5.  Suicide in alcohol-dependent individuals: epidemiology and management.

Authors:  Sami P Pirkola; Kirsi Suominen; Erkki T Isometsä
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

6.  Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy.

Authors:  William Dundon; Kevin G Lynch; Helen M Pettinati; Craig Lipkin
Journal:  Alcohol Clin Exp Res       Date:  2004-07       Impact factor: 3.455

Review 7.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

Review 8.  Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.

Authors:  Katie Witkiewitz; Kevin E Vowles
Journal:  Alcohol Clin Exp Res       Date:  2018-02-06       Impact factor: 3.455

Review 9.  Recent advances in the psychotherapy of addictive disorders.

Authors:  Kathleen M Carroll
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

Review 10.  Relapse Prevention in Alcoholism : Recent Advances and Future Possibilities.

Authors:  M Soyka
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.